Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Explore private companies / Maze Therapeutics IPO
Maze Therapeutics

Maze Therapeutics IPO

$552.39MM
Series D Valuation, Dec 2024
Register for details
For more details on financing and valuation of private companies similar to Maze Therapeutics before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Maze Therapeutics IPO date and status

2018
Founded
Jan 2025
S-1 Filed
Jan 2025
IPO Announced
Jan 2025
IPO Completed

Company details

Maze Therapeutics is a biotechnology company which offers small molecule precision medicines to patients with common diseases. Their approach integrates human genetics, functional genomics, and therapeutic discovery to identify genetic modifiers that may influence disease progression or outcomes. Maze Therapeutics applies its proprietary Compass™ platform striving to incorporate variant functionalization into each stage of drug development. This company was founded by Mark Daly Ph.D, Stephen Elledge Ph.D, Aaron Gitler Ph.D, Sekar Kathiresan MD, and Jonathan Weissman Ph.D in 2018 and is headquartered in South San Francisco, CA.
Founded
2018
Headquarters
South San Francisco, CA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$552.39MM
Total Funding
$503.77MM
Last Funding Round
Series D

Learn more about Maze Therapeutics

To invest in Maze Therapeutics pre-IPO

Can you invest in Maze Therapeutics pre-IPO?

You may invest in Maze Therapeutics as it is a public company listed on the NASDAQ with ticker MAZE. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Maze Therapeutics before it goes public?

You can no longer sell shares of Maze Therapeutics on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Maze Therapeutics shares?

Forge can no longer determine the value of Maze Therapeutics shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Maze Therapeutics a publicly traded company?

Maze Therapeutics became a public company following its IPO on 01/31/2025 and is now traded on the NASDAQ under the ticker MAZE.

To learn more about Maze Therapeutics potential IPO

Will Maze Therapeutics go IPO?

Maze Therapeutics became a public company following its IPO on 01/31/2025 and is now traded on the NASDAQ under the ticker MAZE.

What is Maze Therapeutics’ IPO price?

The IPO price of Maze Therapeutics is not currently available.

When was Maze Therapeutics founded?

Maze Therapeutics was founded in 2018.

What is Maze Therapeutics funding to date?

Maze Therapeutics has raised $503.77MM to date.

Maze Therapeutics major investors

Piper Sandler

Maze Therapeutics pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
12/03/2024 Series D $76.4MM $1.38 $552.39MM Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
Price per Share
$ xx.xx
Shares Outstanding
55,394,431
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
12/03/2024 Series D-1 $43.47MM $1.10 $552.39MM Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
Price per Share
$ xx.xx
Shares Outstanding
39,395,572
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
01/10/2022 Series C $120.62MM $2.95 $742.72MM Andreessen Horowitz, Casdin Capital, City Hill Ventures, Direhaus Capital Management, Foresite Capital, General Catalyst, Matrix Capital Management, Moore Strategic Ventures, Ns Investments, Terra Magnum Capital Partners, Woodline Partners
Price per Share
$ xx.xx
Shares Outstanding
40,866,704
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Casdin Capital, City Hill Ventures, Direhaus Capital Management, Foresite Capital, General Catalyst, Matrix Capital Management, Moore Strategic Ventures, Ns Investments, Terra Magnum Capital Partners, Woodline Partners
10/25/2019 Series B $158.3MM $2.75 $596.01MM City Hill Ventures
Price per Share
$ xx.xx
Shares Outstanding
57,563,188
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
City Hill Ventures
02/28/2019 Series A $104.99MM $1.00 $149.98MM Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, Foresite Capital, Gv, Third Rock Ventures
Price per Share
$ xx.xx
Shares Outstanding
104,985,132
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, Foresite Capital, Gv, Third Rock Ventures

Maze Therapeutics IPO news and media highlights

Drug developer Maze Therapeutics eyes up to $728 million ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering.

Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public. The Bay Area-based biotech revealed the planned IPO in a Jan. 7 filing with the Securities and Exchange Commission but did not divulge how many shares it plans to offer nor at what price. Maze applied to be listed on the Nasdaq under the ticker symbol "MAZE," according to the filing.

Maze Therapeutics Raises $115M in Series D Financing

Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, closed a $115m Series D financing that included the conversion of issued convertible notes previously purchased by existing investors.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Healthcare Software
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Generate BiomedicinesGenerate BiomedicinesNot available$ xx.xxSeries C$2.22B$11.85$399.4MM
OriginOriginNot available$ xx.xxNot available------
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $601.27 +$4.10 (0.69%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.65 -$0.01 (0.01%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.65 -$0.01 (0.01%)High $xxx.xx
Perplexity Perplexity $69.54 +$6.59 (10.47%)High $xxx.xx

Forge, your trusted partner for pre-IPO insights and Maze Therapeutics data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Dec 11, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.